Discovery of a "true" aspirin prodrug

Journal of Medicinal Chemistry

Volumn 51, Issue 24, 2008, Pages 7991-7999

  Moriarty, Louise M ^a   Lally, Maeve N ^a   Carolan, Ciaran G ^a   Jones, Michael ^a   Clancy, John M ^a   Gilmer, John F ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID DERIVATIVE; ACETYLSALICYLIC ACID; BENZOIC ACID DERIVATIVE; CHOLINESTERASE; DRUG METABOLITE; ESTERASE; ISOSORBIDE 2 ASPIRINATE 5 SALICYLATE; ISOSORBIDE 2,5 DIASPIRINATE; PRODRUG; SALICYLIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DERIVATIZATION; DRUG HYDROLYSIS; DRUG SYNTHESIS; ENZYME ACTIVITY; HUMAN; NONHUMAN; THROMBOCYTE AGGREGATION;

ASPIRIN; BUTYRYLCHOLINESTERASE; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ESTERS; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; ISOSORBIDE; KINETICS; MODELS, CHEMICAL; PRODRUGS; TEMPERATURE; TIME FACTORS;

EID: 58149104269     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801094c     Document Type: Article

References (51)

1. Jones, G. Decreased toxicity and adverse reaction via prodrugs. In Design of Prodrugs; Bundgaard, H., Ed.; Elsevier: Amsterdam, The Netherlands, 1985; pp 199-241.
2. St. Pierre, T.; Jencks, W. P. Intramolecular catalysis in the reactions of nucleophilic reagents with aspirin. J. Am. Chem. Soc. 1968, 90, 3817-3827.
3. Testa, B.; Mayer, J. M. Hydrolysis in drug and prodrug metabolism. Chemistry, Biochemistry and Enzymology; Wiley-VCH: Wienheim, Germany, 2003; Chapter 8.
4. Lavis, L. D. Ester bonds in prodrugs. ACS Chem. Biol. 2008, 3203-3206.
5. Levy, G.; Gagliardi, B. A. Gastrointestinal absorption of aspirin anhydride. J. Pharm. Sci. 1963, 52, 730.
6. (a) Ankersen, M.; Nielsen, K. K.; Senning, A. Synthesis, properties and prodrug potential of 2-methyl-2-oxy- and 2-methyl-2-thio-4H-1,3- benzodioxinones. Acta Chem. Scand. 1989, 34, 213-221.
7. (b) Nielsen, K. K.; Senning, A. Aspirin prodrugs: Synthesis of 2-substituted 2-methyl-4H-1,3-benzodioxin-4-ones and their screening for prodrug potential. Acta Chem. Scand. 1990, 44, 952-956.
8. (a) Hussain, A.; Yamasaki, M.; Truelove, J. E. Kinetics of hydrolysis of acylals of aspirin: Hydrolysis of (1′-ethoxy)ethyl 2-acetoxybenzoate. J. Pharm. Sci. 1974, 63, 627-628.
9. (b) Hussain, A.; Truelove, J. E.; Kostenbauder, H. B. Kinetics and mechanism of hydrolysis of 1-(2′-acetoxybenzoyl)-2-deoxy-α- D-glucopyranose, a novel aspirin prodrug. J. Pharm. Sci. 1979, 68, 299-301.
10. Bundgaard, H.; Nielsen, N. M.; Buur, A. Aspirin prodrugs: Synthesis and hydrolysis of 2-acetoxybenzoate esters of various N-(hydroxyalkyl) amides. Int. J. Pharm. 1988, 44, 181-188.
11. Abordo, E. A.; Bowden, K.; Huntington, A. P.; Powell, S. L. Prodrugs. Part 3. 2-Formylphenyl esters of indomethacin, ketoprofen and ibuprofen and 6-substituted 2-formyl and 2-acylphenyl esters of aspirin. Farmacognosia 1998, 53, 95-101.
12. (a) Rainsford, K. D.; Whitehouse, M. W. Anti-inflammatory/antipyretic salicylic acid esters with low gastric ulcerogenic activity. Agents Actions 1980, 10, 451-456.
13. (b) Rainsford, K. D.; Whitehouse, M. W. Gastric irritancy of aspirin and its congeners: Anti-inflammatory activity without this side-effect. J. Pharm. Pharmacol. 1976, 28, 599-601.
14. 14C]carboxylbenzoyl) glycerol. J. Pharm. Pharmacol. 1978, 30, 754-758.
15. (b) Paris, G. Y.; Garmaise, D. L.; Cimon, D. G. Synthesis and anti-inflammatory activity of 1,3-bis(alkanoyl)-2-(O-acetylsalicyloyl) glycerides (aspirin triglycerides). J. Med. Chem. 1979, 22, 683-687.
16. (c) Paris, G. Y.; Garmaise, D. L.; Cimon, D. G.; Swett, L.; Carter, G. W.; Young, P. Glycerides as prodrugs. 2. 1,3-Dialkanoyl-2-(2-methyl-4-oxo-1,3- benzodioxan-2-yl) glycerides (cyclic aspirin triglycerides) as anti-inflammatory agents. J. Med. Chem. 1980, 23, 79-82.
17. Los, M.; Piccinali, C. A.; Tosti, E. L.; Torriani, H. Sintesis de nuevos derivados de los acidos 2-hidroxi (y) 2-acetiloxibenzoico. Boll. Chim. Farm. 1982, 121, 285-302.
18. (a) Lofttson, T.; Bodor, N. Improved delivery through biological membranes XD: Percutaneous absorption and metabolism of methylsulfinylmethyl 2-acetoxybenzoate and related aspirin prodrugs. J. Pharm. Sci. 1981, 70, 756-758.
19. (b) Lofttson, T.; Bodor, N. Improved delivery through biological membranes IX: Kinetics and mechanism of hydrolysis of methylsulfinymethyl 2-acetoxybenzoate and related aspirin prodrugs. J. Pharm. Sci. 1981, 70, 750-755.
20. (c) Lofttson, T.; Kaminski, J. J.; Bodor, N. Improved delivery through biological membranes VIII: Design, synthesis, and in vivo testing of true prodrugs of aspirin. J. Pharm. Sci. 1981, 70, 743-749.
21. (a) Banerjee, P. K.; Amidon, G. L. Physicochemical property modification strategies based on enzyme substrate specificities III: Carboxypeptidase A hydrolysis of aspirin derivatives. J. Pharm. Sci. 1981, 70, 1307-1309.
22. (b) Banerjee, P. K.; Amidon, G. L. Physicochemical property modification strategies based on enzyme substrate specificities II: α-Chymotrypsin hydrolysis of aspirin derivatives. J. Pharm. Sci. 1981, 70, 1304-1306.
23. (c) Banerjee, P. K.; Amidon, G. L. Physicochemical property modification strategies based on enzyme substrate specificities I: Rationale, synthesis, and pharmaceutical properties of aspirin derivatives. J. Pharm. Sci. 1981, 70, 1299-1303.
24. (d) Muhi-Eldeen, Z.; Kawahara, M.; Dakkuri, A.; Hussain, A. Kinetics and mechanism of hydrolysis of aspirin phenylalanine ethyl ester. Int. J. Pharm. 1985, 261, 15-23.
25. Tsunematsu, H.; Ishida, E.; Yoshida, S.; Yamamoto, M. Synthesis and enzymatic hydrolysis of aspirin-basic amino acid ethyl esters. Int. J. Pharm. 1991, 68, 77-86.
26. Jaffar, M.; Everett, S. A.; Naylor, M. A.; Moore, S. G.; Ulhaq, S.; Patel, K. B.; Stratford, M. R.; Nolan, J.; Wardman, P.; Stratford, I. J. Prodrugs for targeting hypoxic tissues: regiospecific elimination of aspirin from reduced indolequinones. Bioorg. Med. Chem. Let. 1999, 4, 113-118.
27. McCoy, C. P.; Rooney, C.; Jones, D. S.; Gorman, S. P.; Nieuwenhuyzen, M. Rational design of a dual-mode optical and chemical prodrug. Pharm. Res. 2007, 24, 194-200.
28. Nielsen, N. M.; Bungaard, H. Evaluation of glycolamide esters and various other esters of aspirin as true aspirin prodrugs. J. Med. Chem. 1989, 32, 727-734.
29. Masson, P.; Froment, M. T.; Fortier, P. L.; Visicchio, J. E.; Bartels, C. F.; Lockridge, O. Butyrylcholinesterase-catalysed hydrolysis of aspirin, a negatively charged ester, and aspirin-related neutral esters. Biochim. Biophys. Acta 1998, 1387, 41-52.
30. Minuz, P.; Lechi, C.; Zuliani, V.; Gaino, S.; Tommasoli, R.; Lechi, A. NO-aspirins: Anti-thrombotic activity of derivatives of acetyl-salicylic acid releasing nitric oxide. Cardiovasc. Drug Rev. 1998, 16, 31-47.
31. Del Soldato, P.; Sorrentino, R.; Pinto, A. NO-aspirins: A class of new anti-inflammatory and antithrombotic agents. Trends Pharmacol. Sci. 1999, 20, 319-323.
32. Velázquez, C. A.; Chen, Q. H.; Citro, M. L.; Keefer, L. K.; Knaus, E. E. Second-generation aspirin and indomethacin prodrugs possessing an O(2)-(acetoxymethyl)-1-(2-carboxypyrrolidin-1-yl)diazenium-1,2-diolate nitric oxide donor moiety: Design, synthesis, biological evaluation, and nitric oxide release studies. J. Med. Chem. 2008, 51, 1954-1961.
33. Gilmer, J. F.; Moriarty, L. M.; Clancy, J. M. Evaluation of nitrate-substituted pseudocholine esters of aspirin as potential nitro-aspirins. Bioorg. Med. Chem. Lett. 2007, 17, 3217-3220.
34. Gilmer, J. F.; Moriarty, L. M.; McCafferty, D. F.; Clancy, J. M. Synthesis, hydrolysis kinetics and anti-platelet effects of isosorbide mononitrate derivatives of aspirin. Eur J. Pharm. Sci. 2001, 14, 221-227.
35. Gilmer, J. F.; Moriarty, L. M.; Lally, M. N.; Clancy, J. M. Isosorbide-based aspirin prodrugs. II. Hydrolysis kinetics of isosorbide diaspirinate. Eur. J. Pharm. Sci. 2002, 16, 297-304.
36. Gilmer, J. F.; Murphy, M. A.; Shannon, J. A.; Breen, C. G.; Ryder, S. A.; Clancy, J. M. Single oral dose study of two isosorbide-based aspirin prodrugs in the dog. J. Pharm. Pharmacol. 2003, 55, 1351-1357.
37. De Luchi, O.; Angius, A.; Filipuzi, F.; Modena, G.; Camera, E. Chemoselective reduction of isosorbide-2,5-dinitrate. Gaz. Chim. Ital. 1987, 117, 173-176.
38. m and the rate of endogenous substrate production (R) from substrate depletion data. Microb. Ecol. 1984, 10, 165-178.
39. Peters, T., Jr. All about Albumin: Biochemistry, Genetics, And Medical Applications; Academic Press Ltd.: London, U.K., 1996.
40. Brimijoin, S.; Hammond, P. Butyrylcholinesterase in human brain and acetylcholinesterase in human plasma: Trace enzymes measured by two-site immunoassay. J. Neurochem. 1988, 51, 1227-1231.
41. Li, B.; Sedlacek, M.; Manoharan, I.; Boopathy, R.; Duysen, E. G.; Masson, P.; Lockridge, O. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem. Pharmacol. 2005, 70, 1673-1684.
42. La Du, B. N.; Snady, H. Esterases of human tissues. Handb. Exp. Pharmacol. 1971, 28, 477-499.
43. Morishita, Y.; Fujii, M.; Kasakura, Y.; Takayama, T. Effect of carboxylesterase inhibition on the anti-tumour effects of irinotecan. J. Int. Med. Res. 2005, 33, 84-89.
44. Pacheco, G.; Palacios-Esquivel, R.; Moss, D. E. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: Selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase. J. Pharmacol. Exp. Ther. 1995, 274, 767-770.
45. Radić, Z.; Pickering, N. A.; Vellom, D. C.; Camp, S.; Taylor, P. Three distinct domains in the cholinesterase molecule confer selectivity for acetyl- and butyrylcholinesterase inhibitors. Biochemistry 1993, 32, 12074-12084.
46. Loewenstein-Lichtenstein, Y.; Glick, D.; Gluzman, N.; Sternfeld, M.; Zakut, H.; Soreq, H. Overlapping drug interaction sites of human butyrylcholinesterase dissected by site-directed mutagenesis. Mol. Pharmacol. 1996, 50, 1423-1431.
47. Thomsen, T.; Kewitz, H.; Pleul, O. A suitable method to monitor inhibition of cholinesterase activities in tissues as induced by reversible enzyme inhibitors. Enzyme 1989, 42, 219-224.
48. Cardinal, D. C.; Flower, R. J. The electronic aggregometer: A novel device for assessing platelet behaviour in whole blood. J. Pharmacol. Methods 1980, 3, 135-158.
49. Ye, T.; Fernández García, C.; McKervey, A. Chemoselectivity and stereoselectivity of cyclisation of R-diazocarbonyls leading to oxygen and sulfur heterocycles catalysed by chiral rhodium and copper catalysts. J. Chem. Soc., Perkin Trans. 1 1995, 1373-1379.
50. Ellman, G. L.; Courtney, K. D.; Andres, V., Jr.; Featherstone, R. M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7, 88-95.
51. Nguyen, T. H.; Burnier, J.; Meng, W. The kinetics of relaxin oxidation by hydrogen peroxide. Pharm. Res. 1993, 10, 1563-1571.